Questions? Call 800-624-6242 About | Ordering | New Menu | Items in cart [0] SEARCH

PAPERBACK price:$33.75 add to cart Rights & Permissions Free PDF Access Sign in to download PDF book and chapters Free Resources Display this book on your site! Related Titles A National Cancer Clinical Trials System for the 21st Century:Reinvigorating the NCI Cooperative Group Program Multi-Center Phase III Clinical Trials and NCI Cooperative Groups: Workshop Summary Other Related Titles Improving the Quality of Cancer Clinical Trials: Workshop Summary (2008) National Cancer Policy Forum (NCPF) Citation Manager Export the bibliographic data for this book in your chosen format Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Citation Manager . "Appendix B: Workshop Speakers, Moderators, and Invited Discussants." Improving the Quality of Cancer Clinical Trials: Workshop Summary. Washington, DC: The National Academies Press, 2008. Please select a format: Page 123   E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Appendix B WORKSHOP SPEAKERS,* MODERATORS,† AND INVITED DISCUSSANTS‡ Ken Anderson, M.D., Dana-Farber Cancer Institute* Don Berry, Ph.D., MD Anderson Cancer Center* David Carbone, M.D., Ph.D., Vanderbilt University* David Chang, M.D., Ph.D., Amgen, Inc.‡ Rick Chappell, Ph.D., University of Wisconsin‡ Jerry Collins, Ph.D., National Cancer Institute‡ Robert Comis, M.D., Coalition of National Cancer Cooperative Groups* Janet Dancey, M.D., National Cancer Institute* James Doroshow, M.D., National Cancer Institute*† Giulio Draetta, M.D., Ph.D., Merck Research Laboratories†‡ Susan Ellenberg, Ph.D., University of Pennsylvania* Jeff Evelhoch, Ph.D., Amgen, Inc.*‡ Gwen Fyfe, M.D., Genentech, Inc.* John Gore, Ph.D., Vanderbilt University* Joe Gray, Ph.D., University of California–San Francisco Comprehensive Cancer Center* Steven Gutman, M.D., Food and Drug Administration* Sam Hanash, M.D., Ph.D., Fred Hutchinson Cancer Research Center‡ Page 123 Front Matter (R1-R12) Introduction (1-2) New Clinical Trial Designs (3-39) Molecular Imaging (40-48) Screening for Predictive Markers (49-66) Costs of Clinical Trials (67-76) Regulatory Issues (77-88) Reports from the Case Study Discussion Groups (89-100) Concluding Remarks (101-101) References (102-106) Acronyms (107-108) Glossary (109-114) Appendix A: Workshop Agenda (115-122) Appendix B: Workshop Speakers, Moderators, and Invited Discussants (123-124)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 123
Improving the Quality of Cancer Clinical Trials: Workshop Summary Appendix B WORKSHOP SPEAKERS,* MODERATORS,† AND INVITED DISCUSSANTS‡ Ken Anderson, M.D., Dana-Farber Cancer Institute* Don Berry, Ph.D., MD Anderson Cancer Center* David Carbone, M.D., Ph.D., Vanderbilt University* David Chang, M.D., Ph.D., Amgen, Inc.‡ Rick Chappell, Ph.D., University of Wisconsin‡ Jerry Collins, Ph.D., National Cancer Institute‡ Robert Comis, M.D., Coalition of National Cancer Cooperative Groups* Janet Dancey, M.D., National Cancer Institute* James Doroshow, M.D., National Cancer Institute*† Giulio Draetta, M.D., Ph.D., Merck Research Laboratories†‡ Susan Ellenberg, Ph.D., University of Pennsylvania* Jeff Evelhoch, Ph.D., Amgen, Inc.*‡ Gwen Fyfe, M.D., Genentech, Inc.* John Gore, Ph.D., Vanderbilt University* Joe Gray, Ph.D., University of California–San Francisco Comprehensive Cancer Center* Steven Gutman, M.D., Food and Drug Administration* Sam Hanash, M.D., Ph.D., Fred Hutchinson Cancer Research Center‡

OCR for page 124
Improving the Quality of Cancer Clinical Trials: Workshop Summary James Heath, Ph.D., California Institute of Technology* Roy Herbst, M.D., Ph.D., MD Anderson Cancer Center*† Hedvig Hricak, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center*† David Jacobson-Kram, Ph.D., Food and Drug Administration* Susan Jerian, M.D., OncoRD, Inc.* Mark Kris, M.D., Memorial Sloan-Kettering Cancer Center* Raju Kucherlapati, Ph.D., Harvard Partners Center for Genetics and Genomics* Steven Larson, M.D., Memorial Sloan-Kettering Cancer Center* Jack Lee, Ph.D., MD Anderson Cancer Center* Pierre Massion, M.D., Vanderbilt University*† Tim McCarthy, Ph.D., Pfizer, Inc.*‡ John Mendelsohn, M.D., MD Anderson Cancer Center*† George Mills, M.D., Parexel International Corporation*† Hal Moses, M.D., Vanderbilt-Ingram Cancer Center* William Pao, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center* David Piwnica-Worms, M.D., Ph.D., Washington University School of Medicine*† Richard Schilsky, M.D., University of Chicago‡ Kevin Schulman, M.D., Duke University Medical School* Lawrence Schwartz, M.D., Memorial Sloan-Kettering Cancer Center* Steven Shak, M.D., Genomic Health, Inc.* Joseph Sparano, M.D., Albert Einstein Comprehensive Cancer Center* Ellen Stovall, National Coalition for Cancer Survivorship* Daniel Sullivan, M.D., Duke University* Daniel Von Hoff, M.D., Translational Genomics Research Institute* John Wagner, M.D., Ph.D., Merck Research Laboratories† Janet Woodcock, M.D., Food and Drug Administration *†